| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SCGB2A2 |
| Uniprot No | Q13296 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-93aa |
| 氨基酸序列 | GSGCPLLENVISKTINPQVSKTEYKELLQEFIDDNATTNAIDELKECFLNQTDETLSNVEVFMQLIYDSSLCDLF |
| 预测分子量 | 15.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SCGB2A2重组蛋白的3篇文献摘要示例(注：部分内容为模拟概括，实际文献需根据具体研究检索)：
---
1. **文献名称**: *Recombinant SCGB2A2 as a Potential Biomarker in Breast Cancer*
**作者**: Smith A, et al.
**摘要**: 本研究通过重组表达SCGB2A2蛋白，验证其在乳腺癌患者血清中的特异性表达，发现其与肿瘤进展相关，提示其作为诊断标志物的潜力。
2. **文献名称**: *Functional Characterization of Recombinant SCGB2A2 in Airway Inflammation*
**作者**: Lee J, et al.
**摘要**: 利用大肠杆菌系统表达SCGB2A2重组蛋白，发现其能抑制气道炎症模型中IL-8的释放，表明其在调节黏膜免疫反应中可能具有抗炎作用。
3. **文献名称**: *Production and Purification of SCGB2A2 for Immunotherapeutic Applications*
**作者**: Chen R, et al.
**摘要**: 优化了哺乳动物细胞表达系统(如CHO细胞)中SCGB2A2重组蛋白的纯化工艺，并验证其诱导肿瘤特异性T细胞应答的能力，为癌症疫苗开发提供基础。
---
**说明**：以上文献为示例性概括，实际文献需通过PubMed、Web of Science等数据库检索关键词(如“SCGB2A2 recombinant”“SCGB2A2 expression”)。SCGB2A2属于分泌球蛋白家族，其重组蛋白研究多集中于疾病标志物、免疫调节或肿瘤治疗领域。
Secretoglobin family 2A member 2 (SCGB2A2), also known as mammaglobin-1. is a low-molecular-weight secretory protein belonging to the secretoglobin superfamily. It is primarily expressed in epithelial tissues, particularly in mammary glands, salivary glands, and respiratory mucosa. Structurally, SCGB2A2 forms disulfide-linked homodimers or heterodimers with related family members like lipophilin B, enabling stable extracellular secretion. Its physiological roles remain incompletely understood but are speculated to involve immune modulation, anti-inflammatory responses, and maintenance of mucosal barrier integrity through ligand binding or enzymatic activity regulation.
Recombinant SCGB2A2 is produced using prokaryotic (e.g., E. coli) or eukaryotic expression systems (e.g., mammalian cells), often fused with tags like His-tag for purification via affinity chromatography. This engineered protein retains native structural features critical for functional studies. Research applications focus on its potential as a diagnostic biomarker, particularly in breast cancer where SCGB2A2 overexpression correlates with tumor progression. Its cancer-specific expression profile enables sensitive detection of circulating tumor cells and micrometastases through RT-PCR or immunoassays. Additionally, recombinant SCGB2A2 serves as an antigenic target for developing antibody-based therapies and cancer vaccines. Emerging studies explore its role in chronic inflammatory diseases and mucosal immunity, leveraging recombinant forms to investigate signaling pathways and therapeutic interventions. Despite technical challenges in maintaining proper protein folding during production, SCGB2A2 remains a valuable tool for both basic research and clinical applications.
×
